Kidney Transplant Recipients Treated With Belatacept Exhibit Increased Naïve and Transitional B Cells - Leibler, C.; Matignon, M.; Pilon, C.; Montespan, F.; Bigot, J.; Lang, P.; Carosella, E. D.; Cohen, J.; Rouas‐Freiss, N.; Grimbert, P.; Menier, C. (American journal of transplantation, 2014)
Keywords: Abatacept; B-Cell Activating Factor - genetics; B-Cell Activating Factor - metabolism; B-Cell Activation Factor Receptor - genetics; B-Cell Activation Factor Receptor - metabolism; BAFF; BAFF‐R; belatacept; Biological and medical sciences; Cells, Cultured; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cohort Studies; CTLA‐4‐Ig; Female; Flow Cytometry; Follow-Up Studies; Graft Rejection - drug therapy; Graft Rejection - immunology; Graft Rejection - metabolism; Humans; Immunoconjugates - therapeutic use; Immunosuppressive Agents - therapeutic use; Kidney Failure, Chronic - surgery; Kidney Transplantation; Male; Medical sciences; Middle Aged; Precursor Cells, B-Lymphoid - cytology; Precursor Cells, B-Lymphoid - metabolism; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - genetics; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the urinary system; transitional B cells; Transplant Recipients; BAFF; Immunoglobulins; transitional B cells; Cytokine; Naive cell; Belatacept; B-Lymphocyte; Homotransplantation; Kidney; Cytotoxic T lymphocyte antigen 4; B cell activating factor receptor; Immunomodulator; BAFF-R; Treatment; Urinary system; Tumor necrosis factor; Surgery; B cell activating factor; Graft; β Cell; Immunosuppressive agent; Fusion protein; CTLA-4-Ig; Kidney transplantation; belatacept; kidney transplantation